All requests are reviewed by qualified healthcare professionals.
- Email: support@novametabolic.com
- Phone: 555
-
English
English
Infectious Disease
Egrifta® (tesamorelin) is a prescription growth hormone-releasing hormone (GHRH) analog used to reduce excess abdominal fat (visceral adiposity) in adults with HIV-associated lipodystrophy. It works by stimulating natural growth hormone production, helping improve body fat distribution in patients living with HIV. Egrifta is administered as a once-daily subcutaneous injection and is used specifically to manage abnormal fat accumulation linked to long-term HIV treatment, not to treat HIV infection itself.
Egrifta® (tesamorelin) is a prescription growth hormone-releasing hormone (GHRH) analog used to reduce excess abdominal fat (visceral adipose tissue) in adults with HIV-associated lipodystrophy. It is administered as a once-daily subcutaneous injection under medical supervision.
Egrifta works by stimulating the release of natural growth hormone, which helps decrease abnormal fat accumulation around the abdomen while supporting improved body composition in eligible patients living with HIV.
Egrifta (tesamorelin) stimulates the pituitary gland to release growth hormone, which helps regulate fat metabolism. This leads to a reduction in excess abdominal fat, a common complication in patients with HIV-related lipodystrophy.
Egrifta is not an antiretroviral medication and does not treat HIV infection itself. It is specifically used to manage fat redistribution associated with long-term HIV therapy and should be used under strict medical supervision.
Possible side effects include injection site reactions, joint pain, swelling, muscle pain, and increased blood sugar levels.
